Data Sheet (Cat.No.T60558)

TargetMol

NSC 694623

Chemical Properties



CAS No. : 907957-34-0

Formula: C16H16N2OS

Molecular Weight: 284.38

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	NSC 694623 is a potent histone acetyltransferase (HAT) inhibitor with an IC50 of 15.9 μM against recombinant HAT p300/CBP-associated factor (PCAF) and exhibits anti-proliferative activity against certain cancer cells, making it useful for anti-cancer research.
Targets(IC50)	Histone Acetyltransferase
In vitro	NSC 694623 exhibits antiproliferative activity against SK-N-SH cells, with an IC50 value of 8.93 μM. Additionally, it inhibits 21% of HCT116 cells at a concentration of 25 μM.[1]

Solubility Information

Solubility	DMSO: 112.5 mg/mL (395.6 mM),Sonication and heating to 60°C are recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (14.07 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.5164 mL	17.5821 mL	35.1642 mL
5 mM	0.7033 mL	3.5164 mL	7.0328 mL
10 mM	0.3516 mL	1.7582 mL	3.5164 mL
50 mM	0.0703 mL	0.3516 mL	0.7033 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Furdas SD, et al. Synthesis and biological testing of novel pyridoisothiazolones as histone acetyltransferase inhibitors. Bioorg Med Chem. 2011;19(12):3678-3689.